Plasma Lipoproteins, Hemostasis and Thrombosis

John H. Griffin; José A. Fernández; Hiroshi Deguchi

doi:10.1055/s-0037-1616236

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 86(01): 386-394
DOI: 10.1055/s-0037-1616236

Research Article

Schattauer GmbH

Plasma Lipoproteins, Hemostasis and Thrombosis

John H. Griffin

¹Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA

,

José A. Fernández

¹Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA

,

Hiroshi Deguchi

¹Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA

› Institutsangaben

Abstract

Summary

Regulation of hemostasis and thrombosis involves numerous plasma factors that contribute to procoagulant and anticoagulant pathways. Lipid-containing surfaces provide sites where both procoagulant and anticoagulant enzymes, cofactors and substrates are assembled to express their activities. Plasma and lipoproteins can contribute to either procoagulant or anticoagulant reactions. Procoagulant lipids/lipoproteins include triglyceride-rich particles in plasma and oxidized low density lipoprotein (LDL) which can accelerate activation of prothrombin, factor X and factor VII. Potentially anticoagulant lipids and lipoproteins, each of which enhances inactivation of factor Va by activated protein C, include phosphatidylethanolamine, cardiolipin, the neutral glycosphingolipids glucosylceramide and Gb3 ceramide (CD77), and high density lipoprotein (HDL). Remarkably, treatment of hyperlipidemia with statins not only lowers lipids but also provides antithrombotic effects whose mechanisms remain to be clarified. We hypothesize that procoagulant and anticoagulant lipids and lipoproteins in plasma may contribute to a Yin-Yang balance that helps influence the up-regulation and down-regulation of thrombin generation.

Key words

Lipoprotein - glycolipid - glucosylceramide - protein C - prothrombinase

Volltext

Referenzen

References
1 Miller GJ. Lipoproteins and the haemostatic system in atherothrombotic disorders. Baillieres Best Pract Res Clin Haematol 1999; 12: 555-75.
2 Miller GJ. Postprandial lipaemia and haemostatic factors. Atherosclerosis 1998; 141: S47-51.
3 Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-8.
4 Mitropoulos KA, Reeves BEA, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coag Fibrinol 1993; 4: 223-34.
5 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9.
6 Miller GJ, Martin JC, Mitropoulos KA, Esnouf MP, Cooper JA, Morrissey JH, Howarth DJ, Tuddenham EG. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood 1996; 87: 4187-96.
7 Miller GJ, Mitropoulos KA, Nanjee MN, Howarth DJ, Martin JC, Esnouf MP, Reeves BE, Miller NE, Cooper JA. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia. Thromb Haemost 1998; 80: 233-8.
8 Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
9 MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb Haemost 2000; 83: 421-6.
10 Mariani G, Bernardi F, Bertina R, Vicente VV, Prydz H, Samama M, Sandset PM, Di Nucci GD, Testa MG, Bendz B, Chiarotti F, Ciarola MV, Strom R. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action “Clotart”. Haematologica 1999; 84: 620-6.
11 Mariani G, Conard J, Bernardi F, Bertina R, Vicente Garcia V, Prydz H, Samama M, Sandset PM, Puopolo M, Ciarla MV, Poso R, Di Nucci GD, Ceci F, Marchetti G. Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated Factor VII. Arterioscler Thromb Vasc Biol 1999; 19: 2024-8.
12 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
13 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-313.
14 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
15 Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
16 Dangas G, Smith DA, Unger AH, Shao JH, Meraji P, Fier C, Cohen AM, Fallon JT, Badimon J, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-92.
17 Fenton JW, Shen GX, Minnear FL, Brezniak DV, Jeske WP, Walenga JM, Bognacki J, Ofosu FA, Hassouna HI. Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol Oncol Clin North Am 2000; 14: 483-90.
18 Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
19 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
20 Goodnight SH, Griffin JH. Herditary thrombophilia. Chapter 127. In: Williams’ Hematology 6^th edition. Beutler E, Lichtman MA, Coller B, Kipps TJ, Seligsohn U. eds. New York: McGraw Hill; 2000: 1697-714.
21 Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res 1997; 88: 67-73.
22 Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8.
23 von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Bartheis M, Scharrer I, Ganser A, Ehrenforth S. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-8.
24 Deguchi H, Fernández JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97: 1907-14.
25 Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
26 Gross PO, Aird WC. The endothelium and thrombosis. Semin Thromb Haemost 2000; 26: 463-78.
27 MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-9.
28 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1.
29 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
30 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
31 Lammle B, Griffin JH. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors. Clin Haematol 1985; 14: 281-342.
32 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
33 Bouma BN, dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis – a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
34 Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256: 5532-5.
35 Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
36 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-6.
37 Mitchell CA, Kelemen SM, Salem HH. The anticoagulant properties of a modified form of protein S. Thromb Haemost 1988; 60: 298-304.
38 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
39 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A 1994; 91: 2728-32.
40 Hackeng TM, van t’ Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
41 van’t Veer C, Hackeng TM, Biesbroeck D, Sixma JJ, Bouma BN. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: An independent anticoagulant function of protein S in plasma. Blood 1995; 85: 1815-21.
42 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
43 Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher Jr CJ. for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New Engl J Med 2001; 344: 699-709.
44 Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-51.
45 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein- associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
46 Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-75.
47 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a “prima ballerina.”. Thromb Haemost 1995; 74: 7-17.
48 Baugh RJ, Broze Jr GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
49 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances Factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
50 Safa O, Hensley K, Smirnov MD, Esmon CT, Esmon NL. Lipid oxidation enhances the function of activated protein C. J Biol Chem 2001; 276: 1829-36.
51 Fernandez JA, Kojima K, Petaja J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cell Mol Dis 2000; 26: 115-23.
52 Bradley WA, Gianturco SH. Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost 1988; 14: 253-7.
53 De Sousa JC, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 940-4.
54 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9.
55 Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18: 458-65.
56 Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E. Blood 1998; 91: 508-15.
57 Xu N, Öhlin AK, Zhou L, Nilsson Å. Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Thromb Res 1995; 80: 35-46.
58 Xu N, Dahlbäck B, Öhlin AK, Nilsson Å. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 1998; 18: 33-9.
59 Saenko EL, Shima M, Sarafanov G. Role of activation of the coagulation Factor VIII in interaction with vWf, phospholipid, and functioning within the Factor Xase complex. Trends Cardiovascular Med 1999; 9: 185-92.
60 Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler Thromb Vasc Biol 2000; 20: 1835-41.
61 Griffin J, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
62 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
63 Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
64 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
65 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
66 Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
67 Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
68 Fisher M, Fernández JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine506 glutamine mutation. Stroke 1996; 27: 1163-6.
69 van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Inter Med 1996; 125: 265-9.
70 Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996; 82: 235-44.
71 de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
72 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
73 Sampram ES, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998; 28: 624-9.
74 Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999; 99: 614-9.
75 Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ. Differential effects of reconsituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost 1997; 77: 303-7.
76 Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, Khan S, Mehta JL. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19: 378-83.
77 Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84: 1011-7.
78 Ichikiwa S, Hirabayshi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends in Cell Biology 1998; 8: 198-202.
79 Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-72.
80 Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14: 111-36.
81 Jacobson K, Dietrich C. Looking at lipid rafts?. Trends Cell Biol 1999; 9: 87-91.
82 Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-4.
83 Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
84 Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal ion-dependent inhibition of activated protein C by 2-macroglobulin and 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin and plasmin. J Biol Chem 1991; 266: 17606-12.
85 Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1990; 63: 48-53.
86 Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation 1991; 84: 293-9.
87 Macko RF, Killewich LA, Fernandez JA, Cox DK, Gruber A, Griffin JH. Brain-specific protein C activation during carotid artery occlusion in humans. Stroke 1999; 30: 542-5.
88 Petaja J, Pesonen E, Fernandez JA, Vent AE, Ramo OJ, Griffin JH. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 1999; 118: 422-9.
89 Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982; 70: 127-34.
90 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
91 Griffin JH. The thrombin paradox. Nature 1995; 378: 337-8.
92 Lentz SR, Fernandez JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR, Heistad DD. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol 1999; 19: 1744-50.
93 Mitropoulos KA, Reeves BE, Miller GJ. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of triglyceride-rich lipoproteins. Blood Coag Fibrinolysis 1993; 4: 943-51.
94 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
95 Harpel PC, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost 1995; 74: 382-6.
96 Ishibashi S. Lipoprotein(a) and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1-2.
97 Angles-Cano E. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Circulation 2000; 102: 184-5.
98 Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, Fukiyama K. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J 1999; 63: 53-8.
99 Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999; 30: 2535-40.